Avid Bioservices Announces Bioproduction Contract with Major Leading Cancer Center
News Nov 23, 2005
Peregrine Pharmaceuticals, Inc. has announced that Avid Bioservices, Inc., Peregrine's wholly owned manufacturing subsidiary, has entered into a manufacturing agreement with the Sidney Kimmel Cancer Center (SKCC) in San Diego.
Under terms of the agreement, Avid will provide process development services to SKCC and will perform cGMP manufacturing of a therapeutic antibody for preclinical studies and clinical trials.
This antibody is initially being tested for the treatment of lung cancer. The contract will start immediately and continue into the 2006 calendar year.
"The Sidney Kimmel Cancer Center is an innovator in its focus on translational research, including supporting the clinical development of promising new cancer therapeutics," said Steven W. King, chief executive officer of Avid.
"Avid's expertise, scale, breadth of service and state-of-the-art manufacturing facility makes us ideally suited to work with SKCC to produce the clinical supplies needed to progress this exciting new drug candidate through the development and regulatory process."
In addition to cGMP manufacture, Avid will conduct all process development for the monoclonal antibody, including production of the initial master cell bank and cell culture and development of all upstream and downstream processes, including assay development, product purification, virus validation, container filling and release testing.
Dr. Jan Schnitzer, M.D., Scientific Director and director of the vascular biology and angiogenesis program at SKCC commented, "Advancing the clinical development of promising new cancer therapies is an important part of our translational research mission, and we are pleased to be working with the highly experienced and supportive bioproduction team at Avid to help us move this novel approach into human trials."
Anti-malaria drugs known as chloroquines have been repurposed to treat cancer for decades, but until now no one knew exactly what the chloroquines were targeting when they attack a tumor. Now, researchers say they have identified that target - an enzyme called PPT1 - opening up a new pathway for potential cancer treatments.READ MORE